triumph-1 retatrutide Eli Lilly and Company Reports Phase 3 TRIUMPH-1 Trial Shows Up to 30.3% Weight Loss with Retatrutide in Obesity

🚨 HOT OFF THE PRESS: Retatrutide Phase 3 data has arrived — and the obesity medicine world is paying attention. In Lilly's TRIUMPH-1 trial, participants receiving the highest dose achieved an average

24.51

★★★★☆4.8 (126)

Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial

23.47

★★★★★4.9 (98)

TRIUMPH-1 Topline Results for Retatrutide (reh-TAH-troo-tide): Mean 28.3% total body weight loss at 80 weeks in people with obesity and without diabetes — with continued loss to 30.3% at 104 weeks in… |

28.70

★★★★★5.0 (157)

Today we shared new results on retatrutide, an investigational, first-of-its-kind treatment we're studying in adults with obesity or overweight with at least one weight-related comorbidity. Read more about the Phase 3 findings:

24.13

★★★★★4.7 (84)

Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials - Giblin - 2026 - Diabetes, Obesity and Metabolism

26.35

★★★★★4.9 (203)

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)

27.84

★★★★★5.0 (176)

Eli Lilly Retatrutide: 28% Weight Loss in Phase 3 Results

29.70

★★★★★4.8 (132)